NCT00651326 - Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 2, 2008

Primary Completion Date

May 14, 2010

Study Completion Date

January 18, 2011

Conditions

Prostate Cancer

Interventions

DRUG

bicalutamide

DRUG

buserelin

DRUG

flutamide

DRUG

goserelin

DRUG

leuprolide acetate

PROCEDURE

neoadjuvant therapy

PROCEDURE

quality-of-life assessment

RADIATION

radiation therapy

"46 Gy in 23 fractions over \< 5 weeks.~Boost:~24-28 Gy in 12-14 fractions over \< 3 weeks"

DRUG

Docetaxel

Trial Locations (13)

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

V1Y 5L3

BCCA - Cancer Centre for the Southern Interior, Kelowna

N6A 4L6

London Regional Cancer Program, London

L5M 2N1

Credit Valley Hospital, Mississauga

H2W 1S6

McGill University - Dept. Oncology, Montreal

L1G 2B9

Lakeridge Health Oshawa, Oshawa

K1H 8L6

Ottawa Health Research Institute - General Division, Ottawa

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg